US3741631036 - Common Stock
NASDAQ:GERN (2/1/2023, 10:34:03 AM)0 (-0.15%)
|GICS Sector||Health Care|
|Earnings (Last)||11-03 2022-11-03/bmo||Earnings (Next)||03-08 2023-03-08|
|Ins Owners||0.13%||Inst Owners||43.24%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 69 full-time employees. The firm operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).The Company has completed the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamic effects of Imetelstat in its Phase I trials.
919 East Hillsdale Boulevard, Suite 250
Foster City CALIFORNIA 94404
CEO: John A. Scarlett
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.
Geron Corporation (GERN) announced new additions to its senior commercial leadership on Wednesday ahead of the planned launch of blood cancer therapy imetelstat. Read the full story here.
Here you can normally see the latest stock twits on GERN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.